Orum Therapeutics Corrects Stock Option Exercise Deadline to October 2031 From October 2036
Bitget2026/10/22 05:12- Orum Therapeutics corrected its shareholder meeting notice on Oct. 22, 2026, shortening Geoffrey Harris Meyerson’s stock option exercise period.
- The corrected period runs from Oct. 24, 2028, through Oct. 23, 2031, rather than Oct. 23, 2036.
- The U.S. subsidiary’s proposed 85,663-share option grant comprises 73,741 shares for CSO Chad May and 11,922 shares for three employees.
- A previously omitted March 27, 2026, grant of 102,223 shares raises total options granted across the reported periods to 799,964 shares.
- Remaining options across those periods were corrected to 729,780 shares from 627,557 shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
